Загрузка...
DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis
Sitagliptin is a dipeptidyl peptidase-4 inhibitor commonly used in the treatment of type 2 diabetes mellitus for glycaemic control. Concerns have arisen regarding adverse events caused by this drug, particularly concerning arthralgias. Here, we report on a 56-year-old man being treated with sitaglip...
Сохранить в:
| Опубликовано в: : | BMJ Case Rep |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BMJ Publishing Group
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6720914/ https://ncbi.nlm.nih.gov/pubmed/31444259 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2018-228981 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|